Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity

Journal of Virology

Volumn 72, Issue 11, 1998, Pages 9233-9246

  Ciarlet, Max ^a   Crawford, Sue E ^a   Barone, Christopher ^a   Bertolotti Ciarlet, Andrea ^a   Ramig, Robert F ^a   Estes, Mary K ^a   Conner, Margaret E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; CESIUM CHLORIDE; FORMALDEHYDE; FREUND ADJUVANT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PSORALEN; QS 21; RECOMBINANT VACCINE; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MUCOSAL IMMUNITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; ROTAVIRUS; VIRUS IMMUNITY; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS PARTICLE;

EID: 0031683188     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.11.9233-9246.1998     Document Type: Article

References (82)

1. Andrew, M. E., D. B. Boyle, B. E. H. Coupar, D. Reddy, A. R. Bellamy, and G. W. Both. 1992. Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhea. Vaccine 10:185-191.
2. Bertolotti-Ciarlet, A., S. E. Crawford, M. E. Conner, and M. K. Estes. Unpublished data.
3. Borriello, S. P., and R. J. Carman. 1983. Association of iota-like toxin and Clostridium spiroforme with both spontaneous and antibiotic-associated diarrhea and colitis in rabbits. J. Clin. Microbiol. 17:414-418.
4. Burns, J. W., H. B. Greenberg, R. D. Shaw, and M. K. Estes. 1988. Functional and topographical analyses of epitopes on the hemagglutinin (VP4) of the simian rotavirus SA11. J. Virol. 62:2164-2172.
5. Burns, J. W., D. Chen, M. K. Estes, and R. F. Ramig. 1989. Biological and immunological characterization of a simian rotavirus SA11 variant with an altered genome segment 4. Virology 169:427-435.
6. Burr, D. H., D. T. Kerner, C. S. Blanco, A. L. Bourgeois, and R. Wistar, Jr. 1987. Gastric lavage: a simple method to obtain IgA-rich intestinal secretions from the rabbit. J. Immunol. Methods 99:277-281.
7. Chen, D., J. W. Burns, M. K. Estes, and R. F. Ramig. 1989. Phenotypes of rotavirus reassortants depend upon the recipient genetic background. Proc. Natl. Acad. Sci. USA 86:3743-3747.
8. Chen, D., M. K. Estes, and R. F. Ramig. 1992. Specific interactions between rotavirus outer capsid proteins VP4 and VP7 determine expression of a cross-reactive, neutralizing VP4-specific epitope. J. Virol. 66:432-439.
9. Christy, C., P. Offit, F. H. Clark, and J. Treanor. 1993. Evaluation of a bovine-human rotavirus reassortant vaccine in infants. J. Infect. Dis. 168: 1598-1599.
10. Ciariet, M., M. Hidalgo, M. Gorziglia, and F. Liprandi. 1994. Characterization of neutralization epitopes on the VP7 surface protein of serotype G11 porcine rotaviruses. J. Gen. Virol. 75:1867-1873.
11. Ciarlet, M., M. K. Estes, and M. E. Conner. 1997. Comparative amino acid sequence analysis of the outer capsid protein VP4 from four lapine rotavirus strains reveals identity with genotype P[14] human rotavirus. Arch. Virol. 142:1059-1069.
12. Ciarlet, M., Y. Hoshino, and F. Liprandi. 1997. Single point mutations may affect the serotype reactivity of serotype G11 porcine rotavirus strains: a widening spectrum? J. Virol. 71:8213-8220.
13. Ciarlet, M., M. K. Estes, C. Barone, R. F. Ramig, and M. E. Conner. 1998. Analysis of host range restriction determinants in the rabbit model: comparison of homologous and heterologous rotavirus infections. J. Virol. 72:2341-2351.
14. Ciarlet, M., M. A. Gilger, C. Barone, M. McArthur, M. K. Estes, and M. E. Conner. Rotavirus disease, but not infection and development of intestinal histophatological lesions, is age-restricted in rabbits. Virology, in press.
15. Clark, H. F., F. E. Borian, L. M. Bell, K. Modesto, V. Gouvea, and S. A. Plotkin. 1988. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J. Infect. Dis. 158:570-587.
16. Clark, H. F., P. A. Offit, R. W. Ellis, D. Krah, A. R. Shaw, J. J. Eiden, M. Pichichero, and J. J. Treanor. 1996. WC3 reassortant vaccines in children. Arch. Virol. Suppl. 12:187-198.
17. Conner, M. E., M. K. Estes, and D. Y. Graham. 1988. Rabbit model of rotavirus infection. J. Virol. 62:1625-1633.
18. Conner, M. E., M. A. Gilger, M. K. Estes, and D. Y. Graham. 1991. Serologic and mucosal immune response to rotavirus infection in the rabbit model. J. Virol. 65:2562-2571.
19. Conner, M. E., S. E. Crawford, C. Barone, and M. K. Estes. 1993. Rotavirus vaccine administered parenterally induces protective immunity. J. Virol. 67: 6633-6641.
20. Conner, M. E., D. O. Matson, and M. K. Estes. 1994. Rotavirus vaccines and vaccination potential. Curr. Top. Microbiol. Immunol. 185:286-337.
21. Conner, M. E., S. E. Crawford, C. Barone, and M. K. Estes. 1994. Rotavirus or virus-like particles administered parenterally induce active immunity, p. 351-355. In F. Brown, R. Chanock, H. Ginsberg, and E. Norrby (eds.), Vaccines 94. Proceedings of Modern Approaches to New Vaccines including Prevention of AIDS, Cold Spring Harbor 1993. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
22. Conner, M. E., and R. F. Ramig. 1996. Enteric diseases, p. 713-743. In N. Nathanson, R. Ahmed, F. González-Scarano, D. E. Griffin, K. V. Homes, F. A. Murphy, and H. L. Robinson, (ed.), Viral pathogenesis. Lippincott-Raven Publishers, Philadelphia, Pa.
23. Conner, M. E., C. D. Zarley, B. Hu, S. Parsons, D. Drabinski, S. Greiner, R. Smith, B. Jiang, B. Corsaro, V. Barniak, H. P. Madore, S. E. Crawford, and M. K. Estes. 1996. Virus-like particles as a rotavirus subunit vaccine. J. Infect. Dis. 174 Suppl. 1:S88-S92.
24. Conner, M. E., S. E. Crawford, C. Barone, C. M. O'Neal, Y.-J. Zhou, F. Fernández, A. Parwani, L. J. Saif, J. Cohen, and M. K. Estes. 1996. Rotavirus subunit vaccines. Arch. Virol. Suppl. 12:199-206.
25. 50 of ALA rabbit rotavirus in rabbits. Arch. Virol. 142:2281-2294.
26. Crawford, S. E., M. Labbé, J. Cohen, M. H. Burroghs, Y.-J. Zhou, and M. K. Estes. 1994. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol. 68:5945-5952.
27. Crawford, S. E., M. K. Estes, M. Ciarlet, C. Barone, C. M. O'Neal, J. Cohen, and M. E. Conner. Induction of heterotypic neutralizing antibodies by rotavirus-like particles. Submitted for publication.
28. Crawford, S. E., and M. K. Estes. Unpublished results.
29. Estes, M. K., D. Y. Graham, E. M. Smith, and C. P. Gerba. 1979. Rotavirus stability and inactivation. J. Gen. Virol. 43:403-409.
30. Estes, M. K., D. Y. Graham, R. F. Ramig, and B. L. Ericson. 1982. Heterogeneity in the structural glycoprotein (VP7) of simian rotavirus SA11. Virology 122:8-14.
31. Estes, M. K., S. E. Crawford, M. E. Peñaranda, B. L. Petrie, J. W. Burns, W.-K. Chan, B. L. Ericson, G. E. Smith, and M. D. Summers. 1987. Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system. J. Virol. 61:1488-1494.
32. Estes, M. K. 1996. Rotaviruses and their replication, p. 1625-1655. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
33. + T cells and antibody are involved in protection against rotavirus infection after systemic immunization with rotavirus-like-particles or inactivated rotavirus, abstr. W20-4, p. 129. In Abstracts of the 16th Annual Meeting of the American Society for Virology.
34. Franco, M. A., and H. B. Greenberg. 1995. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J. Virol. 69:7800-7806.
35. + T cells can mediate complete short-term and partial long-term protection against reinfection by rotavirus. J. Virol. 71:4165-4170.
36. Gorrell, R. J., and R. F. Bishop. 1997. Production of reassortant viruses containing human rotavirus VP4 and SA11 VP7 for measuring neutralizing antibody following natural infection. Clin. Diagn. Lab. Immunol. 4:509-514.
37. Groene, W. S., and R. D. Shaw. 1992. Psoralen preparation of antigenically intact noninfectious rotavirus particles. J. Virol. Methods 38:93-102.
38. Hambraeus, B. A. M., L. E. J. Hambraeus, and G. Wadell. 1989. Animal model of rotavirus infection in rabbits - protection obtained without shedding of viral antigen. Arch. Virol. 107:237-251.
39. Ho, M.-S., R. I. Glass, P. F. Pinsky, N. Young-Okoh, W. M. Sappenfield, J. W. Buehler, N. Gunter, and L. J. Anderson. 1988. Diarrheal deaths in American children. Are they preventable? JAMA 260:3281-3285.
40. Hoshino, Y., L. J. Saif, M. M. Sereno, R. M. Chanock, and A. Z. Kapikian. 1988. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. J. Virol. 62:744-748.
41. Ishida, S. I., N. Feng, J. M. Gilbert, B. Tang, and H. B. Greenberg. 1997. Immune responses to individual rotavirus proteins following heterologous rotavirus infection in mice. J. Infect. Dis. 175:1317-1323.
42. Jiang, B., V. Barniak, C. Barone, C. M. O'Neal, R. Smith, H. P. Madore, M. K. Estes, and M. E. Conner. Rotavirus G1 VLPs induce heterotypic protection in a murine model. Vaccine, in press.
43. Joensuu, J., E. Koskenniemi, X.-L. Pang, and T. Vesikari. 1997. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350:1205-1209.
44. Kapikian, A. Z., Y. Hoshino, R. M. Chanock, and I. Pérez-Schael. 1996. Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Arch. Virol. Suppl. 12:163-175.
45. Kensil, C. R., U. Patel, M. Lennick, and D. Marciani. 1991. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 146:431-437.
46. Kensil, C. R., J.-Y. Wan, and S. Soltysik. 1995. Structural and immunological characterization of the vaccine adjuvant QS-21, p. 525-541. In M. F. Powell and M. J. Newman (ed.), Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, N.Y.
47. Labbé, M., A. Charpilienne, S. E. Crawford, M. K. Estes, and J. Cohen. 1991. Expression of rotavirus VP2 produces empty corelike particles. J. Virol. 65: 2946-2952.
48. LeBaron, C. W., J. Lew, R. I. Glass, J. M. Weber, and G. M. Ruiz-Palacios. 1990. Annual rotavirus epidemic patterns in North America: results of a five-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA 264:983-988.
49. Mackow, E. R., P. T. Vo, R. Broome, D. Bass, and H. B. Greenberg. 1990. Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge. J. Virol. 64:1698-1703.
50. Madore, H. P., M. K. Estes, C. D. Zarley, B. Hu, S. Parsons, D. Drabinski, S. Greiner, R. Smith, B. Jiang, B. Corsaro, V. Barniak, S. Crawford, and M. E. Conner. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine, in press.
51. Malherbe, H. H., and M. Strickland-Cholmley. 1967. Simian virus SA11 and the related O agent. Arch. Gesamte Virusforsch. 22:235-245.
52. Maison, D. O., and M. K. Estes. 1990. Impact of rotavirus infection at a large pediatric hospital. J. Infect. Dis. 162:598-604.
53. Matsui, S. M., P. A. Offit, P. T. Vo, E. R. Mackow, D. A. Benfield, R. D. Shaw, L. Padilla-Noriega, and H. B. Greenberg. 1989. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4. J. Clin. Microbiol. 27:780-782.
54. + cells in resolution of rotavirus infection and protection against reinfection in mice. Virology 214:387-397.
55. McNeal, M. M., M. N. Rae, M. E. Conner, and R. L. Ward. 1998. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-shelled rotavirus particles and QS-21. Virology 243: 158-166.
56. Newman, M. J., J.-Y. Wu, B. H. Gardner, C. A. Anderson, C. R. Kensil, J. Recchia, R. T. Coughlin, and M. F. Powell. 1997. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 15: 1001-1007.
57. Offit, P. A., R. D. Shaw, and H. B. Greenberg. 1986. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins VP3 and VP7. J. Virol. 58:700-703.
58. O'Neal, C. M., S. E. Crawford, M. K. Estes, and M. E. Conner. 1997. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71:8707-8717.
59. O'Neal, C. M., J. D. Clemments, M. K. Estes, and M. E. Conner. 1997. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 72:3390-3393.
60. O'Neal, C. M., R. Carman, and M. E. Conner. Unpublished data.
61. Pérez-Schael, I., M. J. Guntiñas, M. Pérez, V. Pagone, A. M. Rojas, R. González, W. Cunto, Y. Hoshino, and A. Z. Kapikian. 1997. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med. 337:1181-1187.
62. Poruchynsky, M. S., C. Tyndall, G. W. Both, F. Sato, A. R. Bellamy, and P. H. Atkinson. 1985. Deletions into an NH2-terminal hydrophobic domain result in secretion of rotavirus VP7, a resident endoplasmic reticulum membrane glycoprotein. J. Cell Biol. 101:2199-2209.
63. Prasad, B. V. V., G. J. Wang, J. P. M. Clerx, and W. Chiu. 1988. Three-dimensional structure of rotavirus. Mol. Biol. 199:269-275.
64. Prasad, B. V. V., J. W. Burns, E. Marietta, M. K. Estes, and W. Chiu. 1990. Localization of VP4 neutralization sites in rotavirus by 3D cryo-electron microscopy. Nature 343:476-479.
65. Prasad, B. V. V., R. Rothangel, C. Q.-Y. Zeng, J. Jakana, J. A. Lawton, and M. K. Estes. 1996. Visualization of ordered genomic RNA and localization of transcriptional complexes in rotavirus. Nature 382:471-473.
66. Ramig, R. F., and K. L. Galle. 1990. Rotavirus genome segment 4 determines viral replication phenotype in cultured liver cells (HepG2). J. Virol. 64:1044-1049.
67. Ramig, R. F. Unpublished data.
68. Ramig, R. F., and M. E. Conner. Unpublished data.
69. Santosham, M., L. H. Moulton, R. Reid, J. Croll, R. Weatherholt, R. Ward, J. Forro, M. Mack, G. Brenneman, and B. L. Davidson. 1997. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J. Pediatr. 131:632-638.
70. Shaw, A. L., R. Rothangel, D. Chen, R. F. Ramig, W. Chiu, and B. V. V. Prasad. 1993. Three-dimensional visualization of the rotavirus hemagglutinin structure. Cell 74:693-701.
71. Shaw, R. D., W. S. Groene, E. R. Mackow, A. A. Merchant, and E. H. Cheng. 1991. VP4-specific intestinal response to rotavirus in a murine model of heterotypic infection. J. Virol. 65:3052-3059.
72. Tanaka, T. N., M. E. Conner, D. Y. Graham, and M. K. Estes. 1988. Molecular characterization of three rabbit rotavirus strains. Arch. Virol. 98:253-265.
73. Thouless, M. E., R. DiGiacomo, B. J. Deeb, and H. Howard. 1988. Pathogenicity of rotavirus in rabbits. J. Clin. Microbiol. 26:943-947.
74. Vesikari, T. 1993. Clinical trials of live oral rotavirus vaccines: the Finnish experience. Vaccine 11:255-261.
75. Vesikari, T. 1996. Trials of oral bovine and rhesus rotavirus vaccines in Finland: a historical account and present status. Arch. Virol. Suppl. 12:177-186.
76. Vesikari, T. 1997. Rotavirus vaccines against diarrhoeal disease. Lancet 350: 1538-1541.
77. Ward, R. L., D. I. Bernstein, R. Shukla, E. C. Young, J. R. Sherwood, M. M McNeal, M. C. Walker, and G. M. Schiff. 1989. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J. Infect. Dis. 159:79-88.
78. Ward, R. L., D. R. Knowlton, H. B. Greenberg, G. M. Schiff, and D. I. Bernstein. 1990. Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus. J. Virol. 64:2687-2691.
79. Ward, R. L., M. M. McNeal, and J. F. Sheridan. 1990. Development of an adult mouse model for studies on protection against rotavirus. J. Virol. 64: 5070-5075.
80. Ward, R. L., M. M. McNeal, and J. F. Sheridan. 1992. Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. Virology 188:57-66.
81. Ward, R. L., M. M. McNeal, D. S. Sander, H. B. Greenberg, and D. I. Bernstein. 1993. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J. Virol. 67:464-468.
82. Yuan, L., L. A. Ward, B. I. Rosen, T. L. To, and L. J. Saif. 1996. Systemic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J. Virol. 70: 3075-3083.